Canopy Growth Corp director Theresa Yanofsky reported a disposition of company shares linked to tax obligations on vested equity. On March 31, 2026, she sold 10,373 common shares at $0.93 per share, in connection with the vesting of restricted stock units granted on June 3, 2025.
After this tax-related sale, Yanofsky directly holds 53,145 common shares of Canopy Growth. The transaction reflects a routine disposition tied to RSU vesting rather than a discretionary open-market reduction of her overall stake.
ATKINS M SHAN reported open-market sale transactions in this Form 4 filing.
Canopy Growth Corp director M. Shan Atkins disposed of 2,074 common shares on March 31, 2026 at $0.93 per share. According to the disclosure, these shares were originally granted as restricted stock units and the disposition was tied to tax obligations triggered by RSU vesting.
After this tax-related share disposition, Atkins directly holds 41,390 common shares, indicating that only a small portion of her equity position was affected by this routine compensation and tax event.
BAYERN JOSEPH reported open-market sale transactions in this Form 4 filing.
Canopy Growth Corp director Joseph Bayern reported a tax-related share disposition. On March 31, 2026, he disposed of 2,658 Common Shares at $0.93 per share. A footnote explains these shares were originally granted as restricted stock units and the disposition was associated with his tax obligations upon RSU vesting. Following this transaction, he continues to hold 40,000 Common Shares directly.
Canopy Growth Corp director David Angelo Lazzarato reported a disposition of 15,624 common shares at $0.93 per share. According to the footnote, these shares were sold to satisfy tax obligations arising from the vesting of restricted stock units granted on June 3, 2025. After this transaction, he directly holds 72,048 common shares.
Canopy Growth Corporation completed its acquisition of MTL Cannabis, creating what it describes as Canada’s leading medical cannabis business by revenue. Under the arrangement, MTL shareholders received 0.32 Canopy Growth common share and $0.144 in cash per MTL share, for a total of approximately 41.2 million Canopy Growth shares and $18.5 million in cash, all in Canadian dollars.
Canopy Growth also issued 2,956,391 shares to certain former shareholders of Montreal Cannabis Medical in exchange for releasing prior obligations, with these shares subject to an 18‑month transfer restriction. The company highlights expected run‑rate synergies of about $10 million within 18 months and reiterates that integrating MTL’s profitable, cash‑generating operations supports its goal of achieving positive adjusted EBITDA during fiscal 2027. Several MTL leaders have joined Canopy Growth’s senior management, and MTL is now a wholly owned subsidiary whose shares are anticipated to be delisted from the CSE around March 16, 2026.
Canopy Growth Corporation has registered for resale up to 18,705,578 common shares issuable upon exercise of loan warrants held by certain lending investors. These warrants, issued January 8, 2026 under a senior secured loan agreement, allow holders to buy one share at US$1.30 until January 8, 2031.
The company will not receive proceeds from any resale of these shares, but would receive approximately US$24.3 million if all loan warrants are exercised for cash. As of February 4, 2026, 377,862,634 common shares were outstanding. Warrant exercises are generally limited to 4.99% ownership, with an option to increase the cap to 9.99%.
Canopy Growth Corp’s Chief Executive Officer, Luc Mongeau, reported an open-market sale of 9,376 common shares on February 11, 2026. The shares were sold at US$1.0613 per share, which equals C$1.4406 using the Bank of Canada’s February 11, 2026 exchange rate.
The filing explains that these shares had originally been granted as restricted stock units on February 11, 2025, and that the disposition was made to satisfy tax obligations arising from the RSU vesting. After this transaction, Mongeau directly owned 802,992 Canopy Growth common shares.
Canopy Growth Corporation is registering 18,705,578 common shares for resale by lenders holding loan-related warrants. These shares are issuable upon exercise of common share purchase warrants granted to lenders in connection with a US$150,000,000 senior secured loan that carried an original issue discount up to an aggregate principal amount of US$162,115,000.
Each warrant allows the holder to buy one common share at US$1.30 until January 8, 2031, subject to beneficial ownership limits generally starting at 4.99% and potentially increasing to 9.99%. Canopy Growth will not receive proceeds from any resale of shares, but could receive approximately US$24.3 million if all warrants are exercised for cash, which it currently plans to use for investments, potential acquisitions, working capital and general corporate purposes.
Canopy Growth reported Q3 FY2026 results showing stable revenue but much smaller losses and a stronger balance sheet. Net revenue was $74.5M, essentially flat year-over-year, with cannabis net revenue up 4% to $51.6M and Storz & Bickel revenue down 9% to $22.9M.
Consolidated gross margin was 29%, down from 32%, reflecting lower margins in both cannabis and Storz & Bickel. The net loss narrowed by about half to $62.6M, while Adjusted EBITDA loss improved to $(2.9)M. Free cash outflow improved to $(19.0)M from $(28.2)M.
Cash and cash equivalents rose to $371M, giving a net cash position of $146M as of December 31, 2025. Management highlights cost reductions, ongoing annualized savings of $29M, an on-track acquisition of MTL Cannabis, and a January 2026 recapitalization that pushed all debt maturities out to 2031.